Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
NCT06292689Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in vulvar cancer, vaginal cancer, sponsored by Zhejiang Cancer Hospital. Started Mar 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
vulvar cancervaginal cancer
Beyond the preview
Go deeper on NCT06292689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292689.